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Introduction
Variable and suboptimal biospecimen handling prac-tices have been identified as impediments to biomarker
discovery,1,2 including predictive biomarkers for oncology3
indicating a clear and present need for evidence-based, stan-
dardized practices. The United States and international efforts
have been launched to better understand and mitigate variability
during the preanalytical phase and decrease associated effects by
promoting harmonization of procedures both within and across
institutions. The Biorepositories and Biospecimen Research
Branch (BBRB) of the United States National Cancer Institute
(NCI) publishes best practice documents aimed at improving
the quality of data generated from human biospecimens
(https://biospecimens.cancer.gov/bestpractices/overview.asp)
and sponsors research initiatives (https://biospecimens.cancer.
gov/programs/default.asp) and the Biospecimen Research
Database (BRD; http://biospecimens.cancer.gov/brd) to better
understand thresholds and effects of individual preanalytical
factors in biospecimen handling. The BRD allows users to
query both a curated literature repository and standard operat-
ing procedure (SOP) library for a specific preservative, diag-
nosis, analyte, or preanalytical factor. The BRD incorporates
information from international efforts, including those by the
International Society for Biological and Environmental Re-
positories (ISBER) and the European Union-sponsored SPI-
DIA program (standardization and improvement of generic
preanalytical tools and procedures for in vitro diagnostics;
www.spidia.eu), among others.
To facilitate the implementation of evidence-based prac-
tices in biospecimen handling, BBRB has developed a doc-
ument series termed Biospecimen Evidence-Based Practices
(BEBP), which contains step-by-step procedural guidelines
derived from peer-reviewed primary research articles and
expert experience.4 The aim of the BEBP series is to promote
a practical level of standardization and improve overall
biospecimen quality and data reproducibility by specifying
both optimal methods and suitable alternatives, while merging
published evidence with practical knowledge of experts in the
field. The intent of the BEBP is not to serve as a SOP, but to
facilitate the development of evidence-based SOPs by indi-
vidual laboratories.
The present BEBP focuses on nucleic acid extraction from
formalin-fixed, paraffin-embedded (FFPE) tissue biospeci-
mens (see Supplementary Data; Supplementary Data are
available online at www.liebertpub.com/bio). Such biospeci-
mens are being increasingly utilized in genomic research, and
it has become clear over the past decade that variable and
suboptimal FFPE biospecimen collection and processing
practices can alter the quantity and/or quality of extracted
DNA and RNA.5 Concordance between the molecular data
generated with FFPE and snap-frozen biospecimens varies
widely among reports, with correlations ranging from weak
to very strong for the same analytical method.6 While lack
of concordance may be partially attributable to differences
in biospecimen handling during FFPE processing, available
evidence suggests that the extraction method can compound
or mitigate effects introduced during biospecimen collec-
tion, processing, and storage, thus affecting the suitability of
samples for downstream analysis.7–11 When deciding on a
nucleic acid extraction procedure, it is paramount to consider
artifacts that may have been introduced during formalin fixa-
tion and processing, such as nucleic acid fragmentation,12
nucleic acid–protein crosslinking,13,14 denaturation,15,16 and
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additions of methylol groups to nucleic acids.15,17 Importantly,
many such formalin-induced modifications to DNA and RNA
are reversible13,18–21; for example, the addition of a demodi-
fication step as well as optimization of multiple steps during
the extraction procedure can attenuate effects introduced dur-
ing fixation and processing. However, FFPE-specific optimi-
zation steps are interdependent and must be considered
collectively when developing a strategy for extraction. While
several commercial extraction kits are marketed as being tai-
lored for FFPE biospecimens, experts contributing to the
BEBP advised validating any kit for the intended tissue type,
processing regime, and analytical platform before im-
plementation in experimental studies. Validation includes ex-
periments to confirm the feasibility and accuracy of the
intended analytical use, the reproducible performance of the
kit, and the robustness to processing regimes.
Materials and Methods
The BEBP for nucleic acid extraction from FFPE bio-
specimens was built upon a framework of key procedural
steps (or preanalytical factors) during DNA and RNA ex-
traction from FFPE tissue biospecimens that was generated
through an initial survey of the literature and available
SOPs. These preanalytical factors were used to guide tar-
geted searches of the National Library of Medicine (NLM)’s
PubMed database (pubmed.gov) and NCI’s BRD. Published
evidence was compiled regarding how each step or extraction-
specific preanalytical factor affects nucleic acid yield, quality,
integrity, or downstream analysis. The list of potential pre-
analytical factors was expanded through crossreferencing and
pertinent articles were curated for inclusion in the BRD. Once
a draft document was available for review, experts were in-
vited to participate on a review panel based on their expertise
and publication history in the field. Feedback based on the
knowledge, experiences, and opinions of participating experts
was collected primarily through electronic correspondence
both upon review of the original document and in response to
detailed questions. Additional input was captured during a
teleconference after experts had reviewed a complete draft.
Results
The final expert-vetted BEBP document contains step-by-
step procedural guidelines for the extraction of nucleic acids
from FFPE tissue (Supplementary Data). Recommendations
outlined within the procedural guideline section are a cul-
mination of the summarized literature, protocols, and details
from commercial extraction kits, published guidelines by the
Centers for Disease Control and Prevention and the Clinical
& Laboratory Standards Institute Laboratory, and guidance
from the expert panel. As more than one method was often
Table 1. DNA Quality Guidelines by Analytical Platform
Application Criteria employed Reference
NGS Monitor yield after library preparation and mean
insert size as predictors for characterization
success. Age of sample is not a predictor of success,
as fixation technique plays a greater role.
BROAD Institute (http://genomics.broadinstitute.
org/data-sheets/DTS_FFPE_4-2017.pdf)
A minimum of 100 ng DNA is used for library
construction. DNA integrity is not assessed by gel
electrophoresis. Library metrics are used to deter-
mine pass/fail status before sequencing. Successful
libraries should have the majority of library frag-
ments between 300 and 600 bp in size with a
minimum yield of 15 mL at 3 nM.
Dr. Andrew Mungall BC Cancer (www.bcgsc.ca/
services/sequencing-libraries-faq)
Sample intake QC-minimum DNA integrity (>200 bp)
and absence of protein contamination evaluated by
E-Gel.
Dr. Harsha Doddapaneni and Dr. David Wheeler
(Baylor College of Medicine Human Genome
Sequencing Center)
Library construction yields should be >300 ng with
fragments between 200 and 800 bp when using
100 ng input (manual preparation) or 250 ng (ro-
botic preparation).
Post-library capture should have >10 nM yield and
devoid of primer dimers.
150 ng double-stranded DNA, amplification of 100 bp
product; DCt <2 using the FFPE QC Kit
Personal communication Dr. Betsou
(IBBL, Luxembourg)
>6% amplifiable copies; Input adjusted based on PCR
amplification of TBP or FTH1
Sah et al.22
DCt <1.55 real-time PCR-based Illumina FFPE QC Kit Serizawa et al.23
PCR Comparative assessment of differentially sized
GAPDH PCR amplicons: 100, 236, 299, 411,
bp visualized by HPLC
Wang et al.24
aCGH Amplification of a 200 bp fragment of GAPDH from
100 ng DNA
van Beers et al.25
Amplification of 200 bp product; >2 mg DNA Personal Communication Dr. Betsou
(IBBL, Luxembourg)
aCGH, array comparative genomic hybridization; FFPE, formalin-fixed paraffin-embedded; FTH1, ferritin heavy polypeptide 1;
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HPLC, high-performance liquid chromatography; NGS, next-generation sequencing;
PCR, polymerase chain reaction; TBP, tata-binding protein.
supported in the literature and/or by the expert panel, optimal
procedures as well as acceptable alternatives are specified
within the procedural guidelines. In cases where a method or
reagent has detrimental effects, the procedural guidelines state
that it is inadvisable for use with FFPE biospecimens. Lit-
erature summaries within the BEBP are organized by pre-
analytical factor and reflect the data presented in the peer-
reviewed primary research articles identified. Literature
summaries are internally cited with pertinent published liter-
ature. In addition to standard bibliographic information, lit-
erature references include hyperlinks to both the original
article through PubMed and the BRD curation entry. Expert
vetting of the BEBP document resulted in: (1) guidance on
specimen suitability, (2) recommendations for procedural
steps based on the panel’s collective experience, (3) recom-
mendations for platform-specific quality metrics (Tables 1
and 2), and (4) identification of extraction steps for which
there was no consensus from the panel.
SOPs generated based on the guidance provided in the
expert-vetted BEBP will require experimental validation for
the tissue type examined, extraction method employed, and
the downstream analysis that is anticipated. Furthermore, it
is crucial that such optimization and validation are per-
formed on similarly handled and stored FFPE biospecimens
of the same tissue type, as preanalytical factors associated
with the FFPE processing regime and FFPE block storage
may also affect downstream molecular analysis.
Discussion
The BEBP series represents a more granular approach
than the NCI Best Practices for Biospecimen Resources
(https://biospecimens.cancer.gov/bestpractices). The BEBP
document presented in this study reflects an extensive but
pragmatic vetting process that reflects discussions of topics
with limited research evidence as well as assurance that
the recommendations are practical for implementation.
Application-specific guidance for DNA and RNA quality is
provided (Tables 1 and 2), enabling researchers to make an
informed decision as to whether nucleic acids extracted using
a SOP developed under the BEBP are in fact fit for purpose.
Development and implementation of evidence-based SOPs
Table 2. RNA Quality Guidelines by Analytical Platform
Application Criteria employed Reference
RT-PCR Amplification of a 60 bp product; DV200 > 30% Personal Communication Dr. Betsou
(IBBL, Luxembourg)
NGS No RNA Integrity metric (RIN, DV200, etc.) useful in
predicting if a library is successful.
Dr. Hoadley (UNC)
Predictors of success can come from libraries that yield >4 ng/
mL concentration or MiSeq test runs, where goal is to see
>10% of reads mapping to messenger RNA.
RNA capture required between 100 and 200 ng of total RNA
derived from FFPE while Illumina Total RNA-Seq requires
between 400 and 1000 ng.
Following library construction and Agilent/Caliper QC, the
majority of fragments should be between 200 and 500 bp in
length. Final library concentration should be >1 nM in at
least 10 mL.
Dr. Andrew Mungall (BC Cancer)
Ribosomal RNA depletion for RNA-Seq requires a minimum
of 400 ng of total RNA input when quantified by Agilent
Bioanalyzer/Caliper GX. Alternatively, 400 ng of total
nucleic acid quantified by Qubit or Quant-iT can be used.
Sample Intake QC-DV200 should be >30%. RIN is not
informative.
Dr. Harsha Doddapaneni and Dr. David
Wheeler (Baylor College of Medicine
Human Genome Sequencing Center)Library construction yields should be >3 ng with complemen-
tary DNA fragments between 100 and 1,500 bp when using
between 50 and 100 ng RNA input. Greater input is required
for samples with lower DV200 values.
Post-library capture should have >10 nM yield and devoid of
primer dimers.
Microarray >600 ng total RNA (by spectrophotometer); OD 260/280 ratio
>1.5; 3¢/5¢ ratio <100 (as determined by TaqMan-based real
time qRT-PCR of beta-actin using primers located 300 bp
apart); Cy-dye incorporation >4.5 pmol/ng
Penland et al.26
Ratio of real-time PCR amplicons of the 3¢ to the 5¢ end of
beta-actin <20; Cycle threshold of the amplicon of the 5¢ end
of ACTB within seven cycles of the same quantity of
universal control RNA
Roberts et al.27
Mean log ratio slope <0.15 due to the probe’s distance from the
3¢ end or its C-content in microarray hybridization
Duenwald et al.28
DASL >100 ng RNA; A260/280 ratio >1.5; Rpll13a Ct values of <29 Abramovitz et al.29
ACTB, beta-actin; DASL, cDNA-mediated Annealing, Selection, Extension and Ligation; RT-PCR, reverse transcription polymerase
chain reaction.
using the BEBP should prove a valuable tool in improving the
quality and reproducibility of molecular data generated with
FFPE biospecimens. This document can also be found on
BBRB’s website (http://biospecimens.cancer.gov).
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